FDA approves Mylan’s generic Lidoderm patch

PITTSBURGH — Mylan announced Monday that its generic version of Endo Pharmaceutical’s Lidoderm had been approved by the Food and Drug Administration. The Lidocaine Patch 5% is meant to pain from post-herpetic neuralgia. 

 

“Mylan's presentation of this product comes in the form of a thin, lightweight patch, and offers patients a high quality, affordable treatment option within the pain management space,” Mylan CEO Heather Bresch said. “We look forward to continue innovating to meet unmet needs as we deliver on our promise to bring complex, difficult-to-manufacture products to market to benefit patients, providers and payers in the U.S. and around the world."

 

Sales for Lidoderm were about $1.1 billion for the 12 months ending June 30, according to IMS health.